Navigation Links
Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
Date:1/7/2009

SEATTLE, Jan. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that they received $7.5 million pursuant to the joint venture transaction with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) in the United States. In December, the Company received the initial $7.5 million payment in connection with the closing of such transaction. The Company may earn up to an additional $15 million in product sales milestone payments upon achievement of certain revenue targets.

Zevalin, a radioimmunotherapeutic, was exclusively marketed by CTI in the United States since December, 2007 and is now marketed jointly by CTI and Spectrum through RIT Oncology, LLC ("RIT") for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients who have rituximab-refractory follicular NHL. CTI holds a sale option exercisable from January 15, 2009 through July 15, 2009 in its sole discretion to sell its 50% membership interest in RIT to Spectrum for $18 million. The FDA has accepted for filing and review, and has granted priority review status for a supplemental Biologics License Application (sBLA) for use of Zevalin as consolidation therapy in patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy and expects a decision regarding the sBLA in early April, 2009.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a sur
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... (PRWEB) September 23, 2014 The Fish ... rate over the past five years. Growth in per ... has encouraged Canadians to consume more fish and seafood ... food retailers and food-service establishments to increase their purchases ... revenue. Additionally, strong economic growth in much of the ...
(Date:9/23/2014)... The inaugural single day event in Japan ... Tokyo Gardens in Tokyo. Clinical data scientists will meet and ... The second single day event in China will ... The clinical data scientists attending this event will discuss topics ... which display data collected in clinical studies and beyond. ...
(Date:9/23/2014)... Mel Frank, also known as the “Godfather of ... He is perhaps one of the industry’s most important ... a special elective course on growing marijuana on September ... Oaksterdam University in Oakland, California. This day-long seminar ... manicuring, and identifying preflowers and outdoor growing. , The ...
(Date:9/23/2014)... Oaksterdam University has begun publishing a blog ... post, the University addresses the need for quality training ... The cannabis industry is becoming big business. According to ... boost of more than $600 million in revenues and ... the new legal recreational marijuana market in Washington State ...
(Date:9/23/2014)... Mo. Infants, vocalizations throughout the first year ... and cooing to forming syllables and first words. ... amount of vocalizations may differ between hearing and ... that infant vocalizations are primarily motivated by infants, ... with profound hearing loss who received cochlear implants ...
Breaking Medicine News(10 mins):Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2
... A path breaking research published today seems to have ... be able to manufacture their own sperms. Lesbian couples// ... ,Researchers have applied for permission to generate synthetic ... this move will be ethical is a question that ...
... the key to not only stopping heart attacks in ... Researchers at Mount Sinai School of Medicine have shown ... novel contrast agent know as N1177 can detect dangerous, ... findings may help physicians diagnosis a heart attack before ...
... Alirajpur in Jhabua district, beat his wife to death. Reason? ... another young man killed his brother with an arrow when ... owned by him. ,Often the reasons for murders ... entering the neighbour's territory or someone's refusal to lend a ...
... - If you are obese, blame it on your gene. A ... called FTO portray mutation in both their copies, then such people ... people who possess normal copies of the gene. ,Researchers ... of what is happening, this research could give us an answer ...
... M.D., director of the Yale Child Study Center and ... discuss the expansion of the Center’s specialty clinical services ... at Greenwich Library, 101 W. Putnam Ave., Greenwich. ... new clinical services, which will also benefit clients from ...
... Northeastern states in the US are stepping up their efforts ... mercury emissions.// ,Throughout the Northeast, mercury contamination ... that occurs naturally. , It is released ... generating plants. ,Smokestack emissions drift across state ...
Cached Medicine News:Health News:CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 3Health News:Efforts Underway to Fight Alcoholism Among Tribals 4Health News:US States Get Ready to Fight Mercury Pollution 2
(Date:9/23/2014)... , Sept 23, 2014  Vesselon, Inc. today ... Board of Directors, effective September 15, 2014. Dr. Raths, ... as its placement agent to market a private preferred ... and early stroke treatment. "Jurgen,s deep experience ... be a great asset to Vesselon as we develop ...
(Date:9/23/2014)... DALLAS , September 23, 2014 ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible ... Cardiovascular, Cancer, Ophthalmology, Orthopedics) - Global Forecasts to ... Market over the forecast period of 2014 to ... Billion by 2019, at CAGR of 9.6% from ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
Breaking Medicine Technology:Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 41st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4
... Korea , May 10 CrystalGenomics, Inc., a novel ... Ascending Dose) study for its novel antibiotic candidate, CG400549, has been ... , , ... targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme ...
... May 10 Par Pharmaceutical Companies, Inc. (NYSE: ... Generics Limited and Glenmark Generics Inc., USA , has ... that resolves patent litigation related to Glenmark,s challenge to Merck,s ... involving a challenge by Glenmark which sought to launch a ...
Cached Medicine Technology:CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate 2Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R) 2